Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could reduce bleeds in hemophilia a patients

NCT ID NCT07416526

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This Phase 3 trial tests a new drug called NXT007 (Zemocimig) against standard Factor VIII treatment to prevent bleeding in people with severe or moderate hemophilia A who do not have inhibitors. About 126 participants aged 12 and older will receive either NXT007 as a shot under the skin or their usual Factor VIII infusions. The main goal is to see if NXT007 reduces the number of bleeds that need treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NXT007 (Zemocimig)
What this could lead to
If successful, NXT007 could offer a more convenient, less frequent treatment option to prevent bleeding episodes in people with hemophilia A.
What could go wrong
This is a Phase 3 trial, but results may not apply to everyone. NXT007 is a new drug, and its long-term safety and effectiveness compared to standard care are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemophilia A moderately severe hemophilia A severe hemophilia A

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMOPHILIA A

Contacts and locations

Locations

  • Azienda Ospedaliera Universitaria Careggi

    RECRUITING

    Florence, Tuscany, 50134, Italy

  • Chonnam National University Hwasun Hospital

    RECRUITING

    Hwasun-gun, 58128, South Korea

  • Eszak-Pesti Centrumkorhaz - Honvedkorhaz;Diabetologiai Szakrendeles

    RECRUITING

    Budapest, Pest County, 1134, Hungary

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    RECRUITING

    Milan, Lombardy, 20122, Italy

  • Hospital Regional Universitario de Malaga ? Hospital General

    RECRUITING

    Málaga, 29010, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    RECRUITING

    Valencia, 46026, Spain

  • Hospital Universitario La Paz - PPDS

    RECRUITING

    Madrid, 28046, Spain

  • Hospital Universitario Vall d'Hebron - PPDS

    RECRUITING

    Barcelona, 08035, Spain

  • IRCCS Istituto Clinico Humanitas

    RECRUITING

    Rozzano, Lombardy, 20089, Italy

  • Kyung Hee University Hospital at Gangdong

    RECRUITING

    Gangdong-gu, Seoul, 05278, South Korea

  • Nara Medical University Hospital

    RECRUITING

    Kashihara-shi, Nara, 634-8522, Japan

  • Taichung Veterans General Hospital

    RECRUITING

    Taichung, 40705, Taiwan

  • Tokyo Medical University Hospital

    RECRUITING

    Shinjuku-Ku, Tokyo, 160-0023, Japan

  • Tri-Service General Hospital

    RECRUITING

    Taipei, 11490, Taiwan

  • Universitair Medisch Centrum Utrecht

    RECRUITING

    Utrecht, 3584 CX, Netherlands

  • University Hospital of Wales

    RECRUITING

    Cardiff, CF14 4XW, United Kingdom

  • University of Colorado Hemophilia and Thrombosis Center

    RECRUITING

    Aurora, Colorado, 80045-7202, United States

  • University of Iowa Hospitals and Clinics

    RECRUITING

    Iowa City, Iowa, 52242-1009, United States

  • Universitätsklinikum Bonn

    RECRUITING

    Bonn, North Rhine-Westphalia, 53127, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.